{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:55:14Z","timestamp":1790258114297,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016549","name":"Universal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016549","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019402","name":"Puma Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013759","name":"Commonwealth Health Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013759","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016535","name":"Massey Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016535","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.cellsig.2020.109525","type":"journal-article","created":{"date-parts":[[2020,1,5]],"date-time":"2020-01-05T21:34:06Z","timestamp":1578260046000},"page":"109525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Enhanced signaling via ERBB3\/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate]"],"prefix":"10.1016","volume":"68","author":[{"given":"Paul","family":"Dent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Poklepovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Von","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellsig.2020.109525_bb0005","doi-asserted-by":"crossref","first-page":"90262","DOI":"10.18632\/oncotarget.21660","article-title":"Dent P. HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo","volume":"8","author":"Booth","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cellsig.2020.109525_bb0010","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1002\/jcp.27276","article-title":"Neratinib augments the lethality of [regorafenib+sildenafil]","volume":"234","author":"Booth","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.cellsig.2020.109525_bb0015","doi-asserted-by":"crossref","first-page":"6062","DOI":"10.18632\/oncotarget.23681","article-title":"[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration","volume":"9","author":"Booth","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.cellsig.2020.109525_bb0020","article-title":"Neratinib and Entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, G\u03b1q and G\u03b111 and kill uveal melanoma cells","author":"Booth","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.cellsig.2020.109525_bb0025","article-title":"The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib","volume":"20","author":"Booth","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.cellsig.2020.109525_bb0030","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1038\/s41388-019-0849-8","article-title":"Neratinib inhibits Hippo\/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells","volume":"38","author":"Dent","year":"2019","journal-title":"Oncogene."},{"key":"10.1016\/j.cellsig.2020.109525_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2019.109416","article-title":"Signaling alterations caused by drugs and autophagy","volume":"64","author":"Dent","year":"2019","journal-title":"Cell. Signal."},{"key":"10.1016\/j.cellsig.2020.109525_bb0040","doi-asserted-by":"crossref","DOI":"10.1080\/14728222.2019.1691526","article-title":"Not the comfy chair! Cancer drugs that act against multiple active sites","author":"Booth","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.cellsig.2020.109525_bb0045","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3389\/fonc.2019.00650","article-title":"The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib","volume":"9","author":"Booth","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cellsig.2020.109525_bb0050","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.cellsig.2020.109525_bb0055","first-page":"358","article-title":"The target landscape of clinical kinase drugs","author":"Klaeger","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2020.109525_bb0060","doi-asserted-by":"crossref","first-page":"23608","DOI":"10.18632\/oncotarget.8281","article-title":"[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1\/2\/3-PI3K-NF\u03baB compensatory survival signaling","volume":"7","author":"Booth","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.cellsig.2020.109525_bb0065","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s13346-018-0584-7","article-title":"Overcoming transporter-mediated multidrug resistance in cancer: failures and achievements of the last decades","volume":"9","author":"Pa\u0161kevi\u010di\u016bt\u0117","year":"2019","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.cellsig.2020.109525_bb0070","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.4155\/fmc-2018-0366","article-title":"Targeting cancer\u2019s Achilles\u2019 heel: role of BCL-2 inhibitors in cellular senescence and apoptosis","volume":"11","author":"Anantram","year":"2019","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.cellsig.2020.109525_bb0075","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.2174\/1568026619666190119144819","article-title":"Homology Modeling and Docking Studies of Bcl-2 and Bcl-xL with Small Molecule Inhibitors: Identification and Functional Studies","volume":"18","author":"Salam","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.cellsig.2020.109525_bb0080","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","article-title":"BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines","volume":"34","author":"Merino","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellsig.2020.109525_bb0085","doi-asserted-by":"crossref","first-page":"99451","DOI":"10.18632\/oncotarget.19807","article-title":"Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen\/ nitrogen species","volume":"8","author":"Roberts","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.cellsig.2020.109525_bb0090","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/jcp.24961","article-title":"Nexavar\/Stivarga and viagra interact to kill tumor cells","volume":"230","author":"Tavallai","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.cellsig.2020.109525_bb0095","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.32271","article-title":"Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface","volume":"7","author":"Claus","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.cellsig.2020.109525_bb0100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mam.2010.02.003","article-title":"Inhibitors of phosphatidylinositol-3-kinase in cancer therapy","volume":"31","author":"Ihle","year":"2010","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.cellsig.2020.109525_bb0105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pharmthera.2017.02.037","article-title":"PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials","volume":"175","author":"Dey","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cellsig.2020.109525_bb0110","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1515\/hsz-2016-0130","article-title":"The role of Her2 and other oncogenes of the PI3K\/AKT pathway in mitochondria","volume":"397","author":"Rohlenova","year":"2016","journal-title":"Biol. Chem."},{"key":"10.1016\/j.cellsig.2020.109525_bb0115","article-title":"CD95\/Fas and metastatic disease: What does not kill you makes you stronger","volume":"6","author":"Gu\u00e9gan","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.cellsig.2020.109525_bb0120","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41418-018-0254-9","article-title":"Post-translational modifications of Beclin 1 provide multiple strategies for autophagy regulation","volume":"26","author":"Hill","year":"2019","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.cellsig.2020.109525_bb0125","doi-asserted-by":"crossref","first-page":"19620","DOI":"10.18632\/oncotarget.7746","article-title":"The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC\/ERBB3\/c-KIT\/c-MET compensatory survival signaling","volume":"7","author":"Booth","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.cellsig.2020.109525_bb0130","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-18-3382","article-title":"HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma","volume":"25","author":"Fai\u00e3o-Flores","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2020.109525_bb0135","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1158\/1078-0432.CCR-08-0469","article-title":"Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation","volume":"14","author":"Zhang","year":"2008","journal-title":"Clin. Cancer Res."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656820300024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656820300024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:53:01Z","timestamp":1760266381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656820300024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":27,"alternative-id":["S0898656820300024"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2020.109525","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced signaling via ERBB3\/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate]","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2020.109525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109525"}}